復旦張江(01349.HK)擬召開2021年半年度業績說明會
格隆匯8月4日丨復旦張江(01349.HK)公告,擬召開2021年半年度業績說明會。重要內容提示:會議召開時間:2021年8月13日(週五)下午14:00—16:00;會議召開地點:上證路演中心(http://roadshow.sseinfo.com);會議召開方式:網絡互動。
上海復旦張江生物醫藥股份有限公司(以下簡稱“公司”)將於2021年8月12日於上海證券交易所網站(www.sse.com.cn)披露《上海復旦張江生物醫藥股份有限公司2021年半年度報告》。爲加強與投資者的深入交流,使投資者更加全面、深入地瞭解公司情況,公司擬以網絡互動方式召開2021年半年度業績說明會,歡迎廣大投資者積極參與。公司現就2021年半年度業績說明會提前向廣大投資者徵集相關問題,廣泛聽取投資者的意見和建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.